FDA Approves Gloucester Pharmaceuticals’ ISTODAX® for Patients with Cutaneous T-cell Lymphoma

Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration approved ISTODAX(R) (romidepsin) for the treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. (Graphic: Business Wire)